查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085954

肺癌治療市場：2026-2032年全球市場預測（依治療類型、給藥途徑、治療分期、疾病分期、處方狀態、通路、癌症類型及最終用戶分類）

Lung Cancer Therapeutics Market by Therapy Type, Mode Of Administration, Line Of Therapy, Disease Stage, Prescription Status, Distribution Channel, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺癌治療市場將成長至 598.9 億美元，複合年成長率為 8.77%。

主要市場統計數據
基準年 2025 332.3億美元
預計年份：2026年 360.7億美元
預測年份：2032年 598.9億美元
複合年成長率 (%) 8.77%

精準腫瘤學、免疫腫瘤學、抗體藥物偶聯物（ADC）、放射性配體和雙特異性抗體療法，以及非小細胞肺癌（NSCLC）和小細胞肺癌（SCLC）的早期分子篩檢，正在徹底改變肺癌的治療模式。全球癌症監測數據顯示，肺癌仍然是世界上確診病例最多的癌症之一，也是癌症死亡的主要原因之一。這凸顯了開發既能提高存活率又能降低毒性的治療方法的迫切需求。

市場日益呈現以EGFR、ALK、ROS1、BRAF、MET、RET、NTRK、HER2和KRAS G12C突變為標靶的生物標記驅動療法為主的趨勢，此外還包括針對PD-1、PD-L1和CTLA-4的免疫查核點抑制劑。隨著治療流程從晚期轉向輔助性治療、新輔助治療和手術全期手術期治療，商業性機會也從最初的藥物上市表現擴展到伴隨診斷、真實世界數據、准入策略、用藥依從性支持和測序智慧等領域。

肺癌治療格局的變革性變化

肺癌治療格局正從廣泛的化療方案轉向以生物標記主導導向的個人化治療。全面的基因組分析在非小細胞肺癌（NSCLC）的治療管理中發揮核心作用，而液態生物檢體則在組織樣本有限或重複切片檢查不切實際的情況下，提高了檢測的可及性。這些變化正在加速早期識別具有治療意義的突變，從而為轉移性和早期肺癌患者提供更精準的治療選擇。

人工智慧的累積影響

人工智慧（AI）整體對肺癌治療產生累積影響，有助於新藥的發現、臨床試驗的設計以及診斷和治療監測的改進。人工智慧驅動的影像工具可支援早期發現結節和風險分層，而計算生物學則有助於識別最有可能對藥物標靶、抗藥性機制、標靶治療、免疫療法或聯合治療產生反應的患者亞群。

主要肺癌治療市場的關鍵區域洞察。

北美地區憑藉其較高的生物標記檢測普及率、先進的腫瘤學基礎設施、已通過核准的標靶治療和免疫療法的快速應用以及積極參與臨床試驗，仍然是肺癌治療市場的主導地區。在歐洲，精準腫瘤學正透過國家癌症控制計畫、衛生技術評估框架、篩檢計畫和跨境研究網路不斷發展，但各國獲得保險報銷和分子檢測的機會可能有所不同。

針對不同族群肺癌治療策略的關鍵見解

七國集團（G7）透過資助創新、發揮監管領導作用、提供慷慨的癌症治療保險報銷以及建立廣泛的臨床試驗網路，持續對全球肺癌治療市場施加影響。歐盟在協調監管流程、癌症篩檢計畫、合作進行實證研究以及成員國間癌症政策的統一方面發揮著核心作用，而北約成員國則共同構成了一個擁有龐大先進癌症醫療基礎設施、學術研究中心和藥品需求的龐大基礎。

各國對肺癌治療的深入了解

美國在肺癌治療市場擁有舉足輕重的地位，這得益於其創新的法規核准流程、廣泛的臨床試驗活動、基於指南的生物標記檢測以及對標靶治療和免疫療法的積極應用。在加拿大，基於實證醫學的報銷流程和全國統一的癌症評估實踐已經到位。同時，儘管面臨預算限制和公立與私立醫療體系之間的差異，墨西哥和巴西仍在努力擴大癌症治療的覆蓋範圍。英國、德國、法國、義大利和西班牙仍然是重要的歐洲市場，這主要受其各自的衛生技術評估（HTA）決策、癌症治療路徑、篩檢重點和分子檢測項目的影響。另一方面，俄羅斯則面臨醫療體系資金籌措、區域差異和地緣政治壓力等因素造成的治療可及性不平等問題。

為行業領導者提供的實用建議

產業領導者應將生物標記的取得不僅視為臨床需求，更視為推動成長的動力。與病理網路、液態生物檢體提供者、醫院、腫瘤學會和保險公司建立合作關係，可以減少錯失檢測機會，並支持在非小細胞肺癌 (NSCLC) 和某些小細胞肺癌 (SCLC) 病例中合理使用標靶治療和免疫療法。

調查方法

本執行摘要基於對公開可用證據來源的二次研究和分析整合，包括全球癌症流行病學數據、監管批准、臨床實踐指南、同行評審的腫瘤學文獻、臨床實驗室註冊資訊來源、醫療保健技術評估趨勢、報銷政策更新和癌症控制出版物。

結論

肺癌治療正步入一個日益精準、數據驅動且競爭激烈的時代。參與企業，很可能是那些能夠將創新藥物與強大的診斷系統、對保險公司至關重要的證據、人工智慧驅動的運營效率以及覆蓋已開發國家和新興國家醫療保健系統的切實可行的准入策略相結合的公司。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肺癌治療市場：依治療類型分類

  • 化療
    • 烷化劑
    • 含鉑類藥物
    • 紫杉烷類藥物
    • 拓樸異構酶抑制劑
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 放射線治療
    • 近距離放射治療
    • 外部輻射
    • 立體定位放射治療
  • 支持性護理
    • 止吐藥
    • 骨調節劑
    • 造血生長因子
  • 外科手術
  • 標靶治療
    • 間變性淋巴瘤激酶（ALK）抑制劑
    • BRAF抑制劑
    • EGFR抑制劑

第8章 肺癌治療市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服

第9章 肺癌治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第10章 肺癌治療市場：依階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第11章 肺癌治療市場：依處方狀態分類

  • 品牌
  • 非專利的

第12章 肺癌治療市場：依通路分類

  • 線下零售
  • 線上零售

第13章 肺癌治療市場：依癌症類型分類

  • 非小細胞肺癌（NSCLC）
    • 腺癌
    • 大細胞癌
    • 鱗狀細胞癌
  • 小細胞肺癌（SCLC）

第14章 肺癌治療市場：依最終用戶分類

  • 門診靜脈輸液治療中心
  • 癌症中心
  • 居家照護
  • 醫院

第15章 肺癌治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 肺癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 肺癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AstraZeneca PLC
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • Daiichi Sankyo, Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Candel Therapeutics, Inc.
  • Cullinan Therapeutics, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Innovent Biologics（Suzhou）Co., Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • MAIA BIoTechnology, Inc.
  • Nuvalent, Inc.
  • OS Therapies Inc.
  • Sanofi SA
  • Shanghai Henlius BIoTech, Inc.
  • Summit Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-437A5D08AE3F

The Lung Cancer Therapeutics Market is projected to grow by USD 59.89 billion at a CAGR of 8.77% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.23 billion
Estimated Year [2026] USD 36.07 billion
Forecast Year [2032] USD 59.89 billion
CAGR (%) 8.77%

Lung cancer therapeutics are being reshaped by precision oncology, immuno-oncology, antibody-drug conjugates, radioligand and bispecific approaches, and earlier molecular testing across non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). According to global cancer surveillance data, lung cancer remains one of the most frequently diagnosed cancers worldwide and the leading cause of cancer mortality, reinforcing the urgency for therapies that improve survival while reducing toxicity.

The market is increasingly defined by biomarker-directed treatment for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, and KRAS G12C alterations, alongside PD-1, PD-L1, and CTLA-4 immune checkpoint inhibitors. As treatment algorithms move from late-stage disease into adjuvant, neoadjuvant, and perioperative settings, commercial opportunity is expanding beyond drug launch performance to include companion diagnostics, real-world evidence, access strategy, adherence support, and sequencing intelligence.

Transformative Shifts in the Lung Cancer Therapeutics Landscape

The lung cancer treatment landscape has shifted from broad chemotherapy regimens toward personalized, biomarker-led care. Comprehensive genomic profiling is now central to NSCLC management, while liquid biopsy is improving testing access when tissue is limited or repeat biopsy is impractical. These changes are accelerating earlier identification of actionable mutations and enabling more precise therapy selection across metastatic and earlier-stage disease.

Transformative shifts also include immunotherapy combinations, next-generation tyrosine kinase inhibitors, bispecific antibodies, and antibody-drug conjugates designed to address resistance, improve intracranial activity, and extend durable response. In SCLC, where progress has historically been slower, chemo-immunotherapy, DLL3-directed approaches, PARP pathway research, and novel maintenance strategies are creating renewed clinical and commercial momentum.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across lung cancer therapeutics, improving discovery, trial design, diagnostics, and treatment monitoring. AI-enabled imaging tools support earlier nodule detection and risk stratification, while computational biology helps identify drug targets, resistance mechanisms, and patient subgroups most likely to respond to targeted therapy, immunotherapy, or combination regimens.

In clinical development, AI is improving site selection, eligibility matching, protocol feasibility, synthetic control design, pharmacovigilance, and real-world evidence generation. For commercial and medical affairs teams, machine learning can help map testing gaps, therapy sequencing, adherence risks, referral leakage, and regional access barriers. The strongest near-term value will come from governed AI systems integrated with validated clinical data, pathology workflows, imaging repositories, privacy safeguards, and regulatory-grade evidence standards.

Key Regional Insights Across Major Lung Cancer Therapeutics Markets

North America remains a leading region for lung cancer therapeutics due to high biomarker testing adoption, advanced oncology infrastructure, rapid uptake of approved targeted therapies and immunotherapies, and strong participation in clinical trials. Europe continues to expand precision oncology through national cancer plans, health technology assessment frameworks, screening programs, and cross-border research networks, although reimbursement timelines and molecular testing access can vary across countries.

Asia-Pacific is one of the most strategically important regions because of its high disease burden, large patient populations, and elevated prevalence of EGFR-mutated NSCLC in several East Asian populations. Latin America is improving access to immunotherapy and molecular diagnostics, but affordability, referral pathways, and testing infrastructure remain uneven between public and private systems. The Middle East is investing in oncology centers, genomic medicine, and specialist cancer care, particularly in GCC markets, while Africa faces the greatest access challenges, including late diagnosis, limited pathology and radiotherapy capacity, fragmented cancer registries, and constrained reimbursement for innovative lung cancer drugs.

Key Group Insights for Lung Cancer Therapeutics Strategy

The G7 continues to influence global lung cancer therapeutics through innovation funding, regulatory leadership, premium oncology reimbursement, and extensive clinical trial networks. The European Union is central to harmonized regulatory pathways, cancer screening initiatives, joint evidence generation, and cross-country oncology policy alignment, while NATO countries collectively represent a large base of advanced oncology infrastructure, academic research centers, and pharmaceutical demand.

BRICS markets are increasingly important because China, India, Brazil, Russia, and South Africa combine large patient pools, expanding domestic pharmaceutical capabilities, and rising use of targeted therapy where diagnostics and reimbursement are available. ASEAN countries are improving oncology capacity, but access differs substantially between Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines due to variation in insurance coverage, pathology capacity, and specialist availability. GCC markets are prioritizing specialty care investment, genomic testing, public-sector modernization, and medical tourism, creating opportunities for premium lung cancer therapeutics when clinical evidence, reimbursement, and local partnerships align.

Key Country Insights in Lung Cancer Therapeutics

The United States is a highly influential market for lung cancer therapeutics, supported by regulatory innovation pathways, broad clinical trial activity, guideline-driven biomarker testing, and strong adoption of targeted therapy and immunotherapy. Canada follows evidence-based reimbursement processes and pan-Canadian oncology assessment practices, while Mexico and Brazil are expanding oncology access amid budget constraints and variability between public and private systems. The United Kingdom, Germany, France, Italy, and Spain remain critical European markets shaped by national HTA decisions, cancer care pathways, screening priorities, and molecular testing programs, while Russia faces access variability linked to health system funding, regional disparities, and geopolitical pressures.

China is a major growth engine due to high lung cancer incidence, domestic innovation, faster regulatory review for priority therapies, and rapid expansion of targeted therapy and immunotherapy. Japan and South Korea are mature precision oncology markets with strong diagnostics capability, active clinical research, and high relevance for EGFR-directed treatment. India offers significant long-term potential due to a large patient base and rising oncology investment, but requires affordability-focused strategies, broader molecular testing access, and cancer infrastructure expansion. Australia benefits from advanced cancer care, public reimbursement mechanisms, organized clinical trial networks, and active participation in global lung cancer research.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker access as a growth enabler, not only a clinical requirement. Partnerships with pathology networks, liquid biopsy providers, hospitals, oncology societies, and payers can reduce missed testing opportunities and support appropriate use of targeted therapies and immunotherapies across NSCLC and selected SCLC settings.

Organizations should also build evidence strategies that demonstrate survival benefit, quality-of-life impact, sequencing value, safety management, and budget relevance. Successful commercialization will require differentiated positioning in crowded PD-1/PD-L1 and TKI segments, investment in resistance-management pipelines, trial designs that reflect biomarker-defined populations, equitable access models in emerging markets, and compliant AI tools that improve trial execution and real-world decision support.

Research Methodology

This executive summary is based on secondary research and analytical synthesis of publicly available, evidence-based sources, including global cancer epidemiology data, regulatory approvals, clinical practice guidelines, peer-reviewed oncology literature, clinical trial registries, health technology assessment trends, reimbursement policy updates, and cancer control publications.

The methodology emphasizes triangulation across disease burden, treatment standards, biomarker prevalence, regulatory activity, reimbursement environment, diagnostic infrastructure, and regional access conditions. Insights were evaluated for relevance to lung cancer therapeutics, including NSCLC, SCLC, targeted therapies, immunotherapies, antibody-drug conjugates, companion diagnostics, liquid biopsy, resistance mechanisms, real-world evidence, and AI-enabled oncology applications.

Conclusion

Lung cancer therapeutics are entering a more precise, data-intensive, and competitive era. The strongest market participants will be those that connect innovative medicines with diagnostic readiness, payer-relevant evidence, AI-enabled operational efficiency, and practical access strategies across developed and emerging healthcare systems.

As treatment moves earlier in the disease course and resistance mechanisms become central to pipeline planning, durable advantage will depend on integrated oncology ecosystems. Organizations that combine scientific differentiation with regional execution discipline, equitable testing access, and evidence-based sequencing strategies are best positioned to improve outcomes and capture growth in the global lung cancer therapeutics market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Lung Cancer Therapeutics Market, by Therapy Type

  • 7.1. Chemotherapy
    • 7.1.1. Alkylating Agents
    • 7.1.2. Platinum-Based
    • 7.1.3. Taxanes
    • 7.1.4. Topoisomerase Inhibitors
  • 7.2. Immunotherapy
    • 7.2.1. CTLA-4 Inhibitors
    • 7.2.2. PD-1 Inhibitors
    • 7.2.3. PD-L1 Inhibitors
  • 7.3. Radiation Therapy
    • 7.3.1. Brachytherapy
    • 7.3.2. External Beam Radiation
    • 7.3.3. Stereotactic Body Radiation
  • 7.4. Supportive Care
    • 7.4.1. Antiemetics
    • 7.4.2. Bone-Modifying Agents
    • 7.4.3. Hematopoietic Growth Factors
  • 7.5. Surgery
  • 7.6. Targeted Therapy
    • 7.6.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
    • 7.6.2. BRAF Inhibitors
    • 7.6.3. EGFR Inhibitors

8. Lung Cancer Therapeutics Market, by Mode Of Administration

  • 8.1. Inhalation
  • 8.2. Injectable
  • 8.3. Oral

9. Lung Cancer Therapeutics Market, by Line Of Therapy

  • 9.1. First-Line
  • 9.2. Second-Line
  • 9.3. Third-Line & Beyond

10. Lung Cancer Therapeutics Market, by Disease Stage

  • 10.1. Stage I
  • 10.2. Stage II
  • 10.3. Stage III
  • 10.4. Stage IV

11. Lung Cancer Therapeutics Market, by Prescription Status

  • 11.1. Branded
  • 11.2. Generic

12. Lung Cancer Therapeutics Market, by Distribution Channel

  • 12.1. Offline Retail
  • 12.2. Online Retail

13. Lung Cancer Therapeutics Market, by Cancer Type

  • 13.1. Non-Small Cell Lung Cancer (NSCLC)
    • 13.1.1. Adenocarcinoma
    • 13.1.2. Large Cell Carcinoma
    • 13.1.3. Squamous Cell Carcinoma
  • 13.2. Small Cell Lung Cancer (SCLC)

14. Lung Cancer Therapeutics Market, by End User

  • 14.1. Ambulatory Infusion Centers
  • 14.2. Cancer Centers
  • 14.3. Homecare Settings
  • 14.4. Hospitals

15. Lung Cancer Therapeutics Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Lung Cancer Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Lung Cancer Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AstraZeneca PLC
  • 19.2. Merck & Co., Inc.
  • 19.3. F. Hoffmann-La Roche Ltd
  • 19.4. Bristol-Myers Squibb Company
  • 19.5. Regeneron Pharmaceuticals Inc.
  • 19.6. Novartis AG
  • 19.7. Daiichi Sankyo, Inc.
  • 19.8. Pfizer Inc.
  • 19.9. Eli Lilly and Company
  • 19.10. Johnson & Johnson Services, Inc.
  • 19.11. Amgen Inc.
  • 19.12. Takeda Pharmaceutical Company Limited
  • 19.13. GlaxoSmithKline plc
  • 19.14. AbbVie Inc.
  • 19.15. Astellas Pharma Inc.
  • 19.16. Bayer AG
  • 19.17. Boehringer Ingelheim International GmbH
  • 19.18. Candel Therapeutics, Inc.
  • 19.19. Cullinan Therapeutics, Inc.
  • 19.20. Dr. Reddy's Laboratories Ltd.
  • 19.21. Fresenius Kabi AG
  • 19.22. Innovent Biologics (Suzhou) Co., Ltd.
  • 19.23. Jazz Pharmaceuticals, Inc.
  • 19.24. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 19.25. MAIA Biotechnology, Inc.
  • 19.26. Nuvalent, Inc.
  • 19.27. OS Therapies Inc.
  • 19.28. Sanofi S.A
  • 19.29. Shanghai Henlius Biotech, Inc.
  • 19.30. Summit Therapeutics Inc.
  • 19.31. Teva Pharmaceutical Industries Ltd.
  • 19.32. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLATINUM-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLATINUM-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLATINUM-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TAXANES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TAXANES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TAXANES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EXTERNAL BEAM RADIATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EXTERNAL BEAM RADIATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EXTERNAL BEAM RADIATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEREOTACTIC BODY RADIATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STEREOTACTIC BODY RADIATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEREOTACTIC BODY RADIATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIEMETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIEMETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIEMETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMATOPOIETIC GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEMATOPOIETIC GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMATOPOIETIC GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STAGE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STAGE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STAGE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STAGE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STAGE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STAGE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STAGE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STAGE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STAGE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STAGE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STAGE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL STAGE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OFFLINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OFFLINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OFFLINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONLINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONLINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONLINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ADENOCARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADENOCARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SMALL CELL LUNG CANCER (SCLC) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SMALL CELL LUNG CANCER (SCLC) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SMALL CELL LUNG CANCER (SCLC) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 258. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 266. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 296. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 303. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 308. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 311. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 318. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 322. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 323. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 326. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 342. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY